Bicycle Therapeutics PLC (BCYC)
20.54
+0.28
(+1.38%)
USD |
NASDAQ |
Nov 22, 16:00
20.57
+0.03
(+0.15%)
After-Hours: 20:00
Bicycle Therapeutics Cash from Investing (Quarterly): -0.435M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -0.435M |
June 30, 2024 | -0.42M |
March 31, 2024 | -0.012M |
December 31, 2023 | -0.051M |
September 30, 2023 | -0.502M |
June 30, 2023 | -0.277M |
March 31, 2023 | -2.099M |
December 31, 2022 | -1.448M |
September 30, 2022 | -2.984M |
June 30, 2022 | -9.799M |
March 31, 2022 | -4.756M |
December 31, 2021 | -1.067M |
September 30, 2021 | -0.169M |
June 30, 2021 | -0.171M |
Date | Value |
---|---|
March 31, 2021 | -0.623M |
December 31, 2020 | -0.484M |
September 30, 2020 | -0.095M |
June 30, 2020 | -0.301M |
March 31, 2020 | -0.32M |
December 31, 2019 | -0.391M |
September 30, 2019 | -0.283M |
June 30, 2019 | -0.463M |
March 31, 2019 | -0.418M |
December 31, 2018 | -0.41M |
September 30, 2018 | -0.126M |
June 30, 2018 | -0.386M |
March 31, 2018 | -0.264M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-9.799M
Minimum
Jun 2022
-0.012M
Maximum
Mar 2024
-1.320M
Average
-0.4275M
Median
Cash from Investing (Quarterly) Benchmarks
TC BioPharm (Holdings) PLC | -0.0071M |
Adaptimmune Therapeutics PLC | -66.02M |
NuCana PLC | -0.0053M |
Autolus Therapeutics PLC | -9.589M |
Biodexa Pharmaceuticals PLC | -- |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -39.83M |
Cash from Financing (Quarterly) | -31.93M |
Free Cash Flow | -203.53M |
Free Cash Flow Per Share (Quarterly) | -0.5837 |
Free Cash Flow to Equity (Quarterly) | -9.358M |
Free Cash Flow to Firm (Quarterly) | -40.27M |
Free Cash Flow Yield | -19.24% |